Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Prospective, Parallel Group, 2-Part Clinical Food Study to Assess the Safety, Tolerability, and Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointesinal Tracts Are Colonized With Multiple Drug-resistant Organisms

NCT03944369 is registered in ClinicalTrials.gov with Kaleido Biosciences as lead sponsor.

NCT NCT03944369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03944369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Prospective, Parallel Group, 2-Part Clinical Food Study to Assess the Safety, Tolerability, and Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointesinal Tracts Are Colonized With Multiple Drug-resistant Organisms
Lead sponsor
Kaleido Biosciences
Phase
Not applicable
Overall status
Terminated
Start date
June 27, 2019
Completion date
June 16, 2020
Enrollment
3 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

vancomycin-resistant enterococcus, extended-spectrum beta lactamase-producing enterobacteriaceae, or carbapenem-resistant enterobacteriaceae colonized subjects